Clinical trials: Atezolizumab
Neuroendocrine Tumor, Anaplastic Thyroid Cancer
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.
- Conditions
- Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma
- Trial name
- CABATEN (NCT04400474)
- Testing
- Cabozantinib 40 mg
- Where
- 15 sites in Spain
- Volunteers
- 93 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Metastatic Breast Cancer
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy)…
- Trial name
- INDUCE (NCT06793553)
- Testing
- Induction therapy
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Japan Breast Cancer Research Group
Carcinoma, Small Cell Lung
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Prospective, open-label, uncontrolled and multicenter phase I-II study in SCLC patients with ECOG PS 0-1 who have failed one prior platinum-containing line but no more than one chemotherapy-containing line.
- Trial name
- NCT04253145
- Testing
- PM 01183, Atezolizumab
- Where
- 13 sites in Spain
- Volunteers
- 184 people
- Sponsor
- Fundacion Oncosur
Cutaneous Toxicity From ICI Therapy
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to…
- Trial name
- NCT04898751
- Testing
- Immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 2,214 people
- Sponsor
- Johns Hopkins University
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the…
- Conditions
- Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05058651
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 266 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
SIRT and Peri-immunotherapy : a New Concept
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC…
- Trial name
- IMSIRT (NCT06971237)
- Testing
- Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization, Atezolizumab ± Bevacizumab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Solid Tumor, Colorectal Cancer
A Study of KF-0210 in Advanced Solid Tumors Patients
The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Colorectal Cancer, Lung Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT04713891
- Testing
- KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Keythera Pharmaceuticals (Australia) Pty Ltd
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and…
- Trial name
- NCT03041311
- Testing
- Trilaciclib, Carboplatin, Etoposide
- Where
- 45 sites in United States, Bulgaria and 5 more
- Volunteers
- 107 people
- Sponsor
- G1 Therapeutics, Inc.
Advanced Solid Tumor
Trial of INI-4001 in Patients With Advanced Solid Tumours
Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.
- Trial name
- NCT06302426
- Testing
- INI-4001, Nivolumab, Pembrolizumab
- Where
- 3 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Inimmune Corporation
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
- Trial name
- VIRO-25 (NCT06463665)
- Testing
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
- Where
- 15 sites in United States
- Volunteers
- 142 people
- Sponsor
- Genelux Corporation
SCLC, Extensive Stage, Immunotherapy
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Immunotherapy combined with chemotherapy has emerged as the standard of care for patients with extensive-stage small cell lung cancer (ES-SCLC). The incorporation of thoracic radiotherapy can enhance treatment efficacy.
- Conditions
- SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy
- Trial name
- NCT06768307
- Testing
- First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Malignant Melanoma
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-wild type (WT), metastatic, or unresectable locally advanced melanoma who…
- Trial name
- NCT03178851
- Testing
- Atezolizumab, Cobimetinib
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL.
- Trial name
- NCT02500407
- Testing
- BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 713 people
- Sponsor
- Genentech, Inc.
Muscle-invasive Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are…
- Trial name
- IMvigor011 (NCT04660344)
- Testing
- Atezolizumab, Signatera
- Where
- 141 sites in United States, Argentina and 21 more
- Volunteers
- 761 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy based treatment combinations in women with untreated, histologically confirmed, operable, ER+, HER2-negative…
- Trial name
- ECLIPSE (NCT03395899)
- Testing
- Atezolizumab, Cobimetinib, Ipatasertib
- Where
- United Kingdom
- Volunteers
- 71 people
- Sponsor
- Queen Mary University of London
Triple-Negative Breast Cancer
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of tiragolumab in combination with atezolizumab and chemotherapy in participants with metastatic and early triple-negative breast cancer (TNBC).
- Trial name
- NCT04584112
- Testing
- Tiragolumab, Atezolizumab, Nab-paclitaxel
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Extensive-stage Small-cell Lung Cancer
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC).
- Trial name
- NCT06807632
- Testing
- Valemetostat, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or…
- Trial name
- NCT02304393
- Testing
- Atezolizumab, Selicrelumab
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients…
- Trial name
- NCT05746481
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Liza Villaruz, MD